Centessa reports 93% bleed reduction with SerpinPC in 18-month OLE; no safety signals

Centessa Pharmaceuticals plc

Median all-bleeds ABR reduced 93% at 1.2 mg/kg every 2 weeks; median ABR 2.2, 7 of 21 subjects zero bleeds.
No thromboembolic events or treatment-related D-dimer elevations over 18 months; no SerpinPC-related AEs.
Pivotal program advancing: PRESent-5 observation study to start in coming weeks; interventional studies planned for 2023.
Total exposure over 40 patient-years across multiple dosing regimens; sustained safety and tolerability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.